NAS:SAGE (USA) Also trade in: Germany

Sage Therapeutics Inc

$ 184.54 -1.28 (-0.69%)
Volume: 286,544 Avg Vol (1m): 398,287
Market Cap $: 9.44 Bil Enterprise Value $: 8.09 Bil
P/E (TTM): 0.00 P/B: 6.81
Earnings Power Value -169.24
Net Current Asset Value 26.15
Tangible Book 27.21
Projected FCF -6.63
Median P/S Value 154.65
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9.8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
N/A
Equity-to-Asset 0.93
Equity-to-Asset range over the past 10 years
Min: 0.91, Med: 0.93, Max: 0.95
Current: 0.93
0.91
0.95
Interest Coverage No Debt
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 53.33
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 19.83%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -534.47
Operating Margin range over the past 10 years
Min: -534.47, Med: -435.61, Max: -435.61
Current: -534.47
-534.47
-435.61
Net Margin % -508.82
Net Margin range over the past 10 years
Min: -508.82, Med: -413.06, Max: -413.06
Current: -508.82
-508.82
-413.06
ROE % -43.49
ROE range over the past 10 years
Min: -79.92, Med: -63.94, Max: -43.49
Current: -43.49
-79.92
-43.49
ROA % -40.84
ROA range over the past 10 years
Min: -321.6, Med: -57.81, Max: -40.84
Current: -40.84
-321.6
-40.84
ROC (Joel Greenblatt) % -9303.46
ROC (Joel Greenblatt) range over the past 10 years
Min: -42160.36, Med: -16925, Max: -7408.46
Current: -9303.46
-42160.36
-7408.46
3-Year Total EBITDA Growth Rate -60.70
3-Year EBITDA Growth Rate range over the past 10 years
Min: -106.9, Med: -76.5, Max: -35.7
Current: -35.7
-106.9
-35.7
3-Year EPS w/o NRI Growth Rate -33.40
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -48.55, Max: -33.4
Current: -33.4
0
-33.4

» SAGE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SAGE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:MRNA NAS:SRPT NAS:ALNY SZSE:000661 NAS:BLUE NAS:TECH NAS:JAZZ HKSE:06160 NAS:IONS OCSE:GEN NAS:NBIX SZSE:002252 TSE:4587 NAS:AMRN XAMS:GLPG NAS:SGEN NAS:EXEL SZSE:002007 NAS:NKTR NAS:ASND
Traded in other countries SG7.Germany
Address 215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. Sage's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

Ratios

Current vs industry vs history
PB Ratio 6.81
PB Ratio range over the past 10 years
Min: 4.45, Med: 6.41, Max: 8.74
Current: 6.81
4.45
8.74
PS Ratio 94.61
PS Ratio range over the past 10 years
Min: 42.24, Med: 79.31, Max: 98.13
Current: 94.61
42.24
98.13
EV-to-EBIT -16.70
EV-to-EBIT range over the past 10 years
Min: -27.6, Med: -15.3, Max: -7.4
Current: -16.7
-27.6
-7.4
EV-to-EBITDA -16.73
EV-to-EBITDA range over the past 10 years
Min: -27.6, Med: -15.3, Max: -7.4
Current: -16.73
-27.6
-7.4
EV-to-Revenue 89.13
EV-to-Revenue range over the past 10 years
Min: 32.3, Med: 67.2, Max: 83
Current: 89.13
32.3
83
Current Ratio 20.06
Current Ratio range over the past 10 years
Min: 1.99, Med: 14.95, Max: 28.92
Current: 20.06
1.99
28.92
Quick Ratio 20.06
Quick Ratio range over the past 10 years
Min: 1.99, Med: 14.95, Max: 28.92
Current: 20.06
1.99
28.92

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.00
3-Year Share Buyback Rate range over the past 10 years
Min: -17.9, Med: -15.6, Max: -4.9
Current: -17
-17.9
-4.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.78
Price-to-Tangible-Book range over the past 10 years
Min: 3.57, Med: 6.77, Max: 14.55
Current: 6.78
3.57
14.55
Price-to-Median-PS-Value 1.19
Price-to-Median-PS-Value range over the past 10 years
Min: 0.63, Med: 0.97, Max: 1.24
Current: 1.19
0.63
1.24
Earnings Yield (Joel Greenblatt) % -6.01
Earnings Yield (Greenblatt) range over the past 10 years
Min: -13.5, Med: -6.6, Max: -3.6
Current: -6.01
-13.5
-3.6

More Statistics

Revenue (TTM) (Mil) $ 90.74
EPS (TTM) $ -9.74
Beta 2.64
Volatility % 61.32
52-Week Range $ 79.88 - 193.56
Shares Outstanding (Mil) 51.15

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y